240 related articles for article (PubMed ID: 19452249)
1. Differentiation of FDG-avid loco-regional recurrent and compromised benign lesions after surgery for breast cancer with dual-time point F-18-fluorodeoxy-glucose PET/CT scan.
Suga K; Kawakami Y; Hiyama A; Matsunaga N
Ann Nucl Med; 2009 Jun; 23(4):399-407. PubMed ID: 19452249
[TBL] [Abstract][Full Text] [Related]
2. Differential diagnosis between (18)F-FDG-avid metastatic lymph nodes in non-small cell lung cancer and benign nodes on dual-time point PET/CT scan.
Suga K; Kawakami Y; Hiyama A; Sugi K; Okabe K; Matsumoto T; Ueda K; Tanaka N; Matsunaga N
Ann Nucl Med; 2009 Aug; 23(6):523-31. PubMed ID: 19444550
[TBL] [Abstract][Full Text] [Related]
3. Dual-time point 18F-FDG PET/CT scan for differentiation between 18F-FDG-avid non-small cell lung cancer and benign lesions.
Suga K; Kawakami Y; Hiyama A; Sugi K; Okabe K; Matsumoto T; Ueda K; Tanaka N; Matsunaga N
Ann Nucl Med; 2009 Jul; 23(5):427-35. PubMed ID: 19437097
[TBL] [Abstract][Full Text] [Related]
4. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
[TBL] [Abstract][Full Text] [Related]
5. The clinical value of texture analysis of dual-time-point
Nakajo M; Jinguji M; Aoki M; Tani A; Sato M; Yoshiura T
Eur Radiol; 2020 Mar; 30(3):1759-1769. PubMed ID: 31728684
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic performance of CT attenuation values of focal 18F-FDG avid breast lesions detected on whole-body PET-CT in postoperative breast cancer patients.
Plaza MJ; Collado-Mesa F; Bokhoor J; Alperin N; Yepes MM
Breast J; 2014; 20(3):235-42. PubMed ID: 24750508
[TBL] [Abstract][Full Text] [Related]
7. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions.
Lan XL; Zhang YX; Wu ZJ; Jia Q; Wei H; Gao ZR
Clin Radiol; 2008 Jul; 63(7):756-64. PubMed ID: 18555033
[TBL] [Abstract][Full Text] [Related]
8. FDG-PET/CT for the early prediction of histopathological complete response to neoadjuvant chemotherapy in breast cancer patients: initial results.
Buchbender C; Kuemmel S; Hoffmann O; Stahl AR; Kimmig R; Otterbach F; Ladd S; Koeninger A; Forsting M; Bockisch A; Antoch G; Heusner TA
Acta Radiol; 2012 Jul; 53(6):628-36. PubMed ID: 22761341
[TBL] [Abstract][Full Text] [Related]
9. Quantification of FDG-PET/CT with delayed imaging in patients with newly diagnosed recurrent breast cancer.
Baun C; Falch K; Gerke O; Hansen J; Nguyen T; Alavi A; Høilund-Carlsen PF; Hildebrandt MG
BMC Med Imaging; 2018 May; 18(1):11. PubMed ID: 29743027
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic accuracy of (18)F-FDG PET/CT compared with that of contrast-enhanced MRI of the breast at 3 T.
Magometschnigg HF; Baltzer PA; Fueger B; Helbich TH; Karanikas G; Dubsky P; Rudas M; Weber M; Pinker K
Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1656-1665. PubMed ID: 26121928
[TBL] [Abstract][Full Text] [Related]
11. The role of ¹⁸F-FDG uptake features in the differential diagnosis of solitary pulmonary lesions with PET/CT.
Zhao M; Chang B; Wei Z; Yu H; Tian R; Yuan L; Jin H
World J Surg Oncol; 2015 Sep; 13():271. PubMed ID: 26369407
[TBL] [Abstract][Full Text] [Related]
12. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
[TBL] [Abstract][Full Text] [Related]
13. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
14. Dual time point FDG-PET/CT imaging... Potential tool for diagnosis of breast cancer.
Zytoon AA; Murakami K; El-Kholy MR; El-Shorbagy E
Clin Radiol; 2008 Nov; 63(11):1213-27. PubMed ID: 18929039
[TBL] [Abstract][Full Text] [Related]
15. Texture analysis on (18)F-FDG PET/CT images to differentiate malignant and benign bone and soft-tissue lesions.
Xu R; Kido S; Suga K; Hirano Y; Tachibana R; Muramatsu K; Chagawa K; Tanaka S
Ann Nucl Med; 2014 Nov; 28(9):926-35. PubMed ID: 25107363
[TBL] [Abstract][Full Text] [Related]
16. A stepwise approach using metabolic volume and SUVmax to differentiate malignancy and dysplasia from benign colonic uptakes on 18F-FDG PET/CT.
Oh JR; Min JJ; Song HC; Chong A; Kim GE; Choi C; Seo JH; Bom HS
Clin Nucl Med; 2012 Jun; 37(6):e134-40. PubMed ID: 22614211
[TBL] [Abstract][Full Text] [Related]
17. Correlation Between
Yu P; Lei J; Xu B; Wang R; Shen Z; Tian J
Acad Radiol; 2020 May; 27(5):682-688. PubMed ID: 31311773
[TBL] [Abstract][Full Text] [Related]
18. Serial changes of FDG uptake and diagnosis of suspected lung malignancy: a lesion-based analysis.
Cheng G; Alavi A; Werner TJ; Del Bello CV; Akers SR
Clin Nucl Med; 2014 Feb; 39(2):147-55. PubMed ID: 24368534
[TBL] [Abstract][Full Text] [Related]
19. Dual-time point 18FDG-PET/CT imaging may be useful in assessing local recurrent disease in high grade bone and soft tissue sarcoma.
Dancheva Z; Bochev P; Chaushev B; Yordanova T; Klisarova A
Nucl Med Rev Cent East Eur; 2016; 19(1):22-7. PubMed ID: 26841376
[TBL] [Abstract][Full Text] [Related]
20. Early SUV
Zhang J; Shi X; Xiao Y; Ma C; Cao G; Liu Y; Li Y
Quant Imaging Med Surg; 2021 May; 11(5):1680-1691. PubMed ID: 33936956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]